The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
In her early thirties, Aisling McCarthy battled severe pain from arthritis and fibromyalgia, leading to emotional eating and significant weight gain. After trying various diets without lasting success, she turned to Ozempic, which drastically improved her health and mobility. She warns against common errors like neglecting mental health, emphasizing gradual weaning to sustain results.
The trend of using GLP-1 medications like Ozempic for weight loss has led to a phenomenon known as 'Ozempic face,' marked by sunken eyes and defined facial features. Celebrities and regular individuals alike have embraced these drugs, with over 10% of Americans reportedly using them in 2025. From Oprah to Elon Musk, several high-profile figures have experienced noticeable changes in their appearances.
A recent study from Cornell University highlights the profound impact of weight-loss medications such as Ozempic on grocery shopping behaviors in the US. Researchers analyzed data from over 150,000 households, revealing substantial changes in spending on various food items following GLP-1 usage. These findings underscore broader trends in consumer demand influenced by these popular drugs.
This article explores the growing prevalence of weight-loss injections such as Ozempic in everyday life. It highlights rising adoption rates in the UK and US, potentially transforming workplace dynamics. Key statistics from research providers underscore the trend.
Over 500,000 Californians may lose access to popular GLP-1 weight loss drugs from January 1, 2026, as the state opts out of covering these prescriptions under Medi-Cal for non-medical purposes. The move targets cost savings after federal cuts, while allowing coverage for diabetes and other conditions.
Novo Nordisk has faced challenges with its stock and leadership due to the weight loss drug market. While scientists see potential in GLP-1 medications expanding beyond diabetes and obesity, investors are losing patience. Ongoing research highlights additional benefits like reducing cravings and aiding brain functions.
Eli Lilly's Mounjaro, a groundbreaking GLP-1 agonist, is altering the landscape of obesity and diabetes management in the US. This article explores its market success, addresses key patient challenges, and delves into the investment implications for LLY stock, highlighting growth drivers and potential risks.
Weight-loss injections such as Ozempic have altered festive meal preparations for many Brits. Recent studies show changes in buying habits and rising concerns among hosts. Health tracking tools can aid in monitoring these shifts.
Experts in eating disorders express alarm over the swift introduction of GLP-1 weight-loss drugs through telehealth platforms and intense social media promotions by certain firms. One instance highlighted references to restrictive Australian regulations hindering detailed medication info for buyers. The Australia and New Zealand Academy for Eating Disorders fears such tactics might appeal to those who don't require the drugs.
